Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Barclays PLC grew its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 587.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 114,075 shares of the company’s stock after buying an additional 97,493 shares during the quarter. Barclays PLC owned 0.17% of Perspective Therapeutics worth $1,523,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CATX. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE boosted its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the second quarter worth about $117,000. Point72 DIFC Ltd purchased a new position in Perspective Therapeutics during the second quarter worth about $118,000. Finally, Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $137,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Price Performance

NYSE CATX opened at $3.50 on Monday. The company’s 50 day moving average is $5.16 and its 200-day moving average is $10.25. Perspective Therapeutics, Inc. has a 12-month low of $2.70 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. On average, equities analysts expect that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

CATX has been the topic of several analyst reports. Oppenheimer cut their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Wedbush restated an “outperform” rating and set a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Insider Activity

In other news, Director Heidi Henson bought 25,975 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average price of $3.85 per share, with a total value of $100,003.75. Following the acquisition, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 67,570 shares of company stock valued at $256,789 over the last quarter. Company insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.